Clinical Trial Update: Safety and Efficacy of Pegylated Exenatine Injection (PB-119) in Drug-naïve T2DM Subjects [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating the safety and efficacy of Pegylated Exenatine Injection (PB-119) in drug-naïve patients with type 2 diabetes mellitus has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Pegylated Exenatine Injection (PB-119)

Snippet

Sponsor: PegBio Co., Ltd. | Conditions: Type 2 Diabetes Mellitus (T2DM) | Phase 3 | Status: COMPLETED